Neuralink's valuation has surged in secondary markets to marks between $42 billion and $59.8 billion as of October 2026, driven by expanded human trials involving over 20 participants, record cursor-control speeds of 11.32 bits per second from pretrained decoders, and FDA breakthrough designations for vision and speech applications. This represents a more than fivefold increase from the $9–9.7 billion post-money valuation of its $650 million Series E in mid-2025, fueled by sustained investor demand for brain-computer interface technology amid limited primary funding updates. Private-market pricing reflects optimism around clinical data accumulation and Musk-linked ecosystem synergies, though resolution depends on verifiable Nasdaq Private Market quotes through year-end amid inherent illiquidity and potential regulatory or trial milestones.